1-hydroxycyclopropane-1-carboxylic acid

We are 1-hydroxycyclopropane-1-carboxylic acid CAS:17994-25-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:1-hydroxycyclopropane-1-carboxylic acid
CAS.NO:17994-25-1
Synonyms:1-hydroxycyclopropane-1-carboxylic acid
1-hydroxycyclopropylcarboxylic acid
1-Hydroxy-1-cyclopropanecarboxylic acid
1-hydroxycyclopropane carboxylic acid
1-hydroxy-1-cyclopropanecarboxylic
Molecular Formula:C4H6O3
Molecular Weight:102.08900
 
Physical and Chemical Properties:
Density:1.676
Melting point:108-110ºC
Boiling point:276.6ºC
Flash point:135.3ºC
 
Specification:
Appearance:White to light orange powder 
Assay:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:A hydroxycarboxylic acid as additive enhancing topical actions of therapeutic agents.

1-hydroxycyclopropane-1-carboxylic acid


Related News: The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.4 '- (3-metil-2-butyeniloxi) benzaldehído CAS:28090-12-2 The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.Ácido D-glutámico CAS:6893-26-1 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.128438-01-7 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.

Related Products
Product Name
2-Formylbenzenesulfonic Acid Sodium Salt View Details
phenyl isothiocyanate View Details
H-LEU-VAL-OH View Details
5-Fluoro-2-nitrobenzoic acid manufacturer (1-benzoyl-2-oxo-4-phenylazetidin-3-yl) acetate manufacturer (S)-2-Aminopropanamide hydrochloride manufacturer 2-nitro-1-N-phenylbenzene-1,4-diamine manufacturer (R,R)-2-amino-1-(4-nitrophenyl)propane-1,3-diol manufacturer